- Conditions
- Kidney Transplant; Complications
- Interventions
- Extended Release Tacrolimus Tablets, Immediate Release Tacrolimus Capsule
- Drug
- Lead sponsor
- Roy D. Bloom, MD
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 159
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Kidney Transplantation
- Interventions
- CFZ533 - Cohort 1/Cohort 2, Mycophenolate Mofetil (MMF), Corticosteroids (CS), Tacrolimus, Induction therapy: basiliximab, Induction therapy: rabbit anti-thymocyte globulin (rATG), Maintenance population: EC-MPS, Maintenance population: MMF, Placebo 1 mL
- Biological · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 418 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 15
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 10 more
- Conditions
- Immune Tolerance
- Interventions
- Immune tolerance after kidney transplant, Donor blood stem cells and T cells
- Procedure · Drug
- Lead sponsor
- Samuel Strober
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 2
- States / cities
- Palo Alto, California • Madison, Wisconsin
- Conditions
- Type 1 Diabetes
- Interventions
- Rapamycin, Mycophenolate Mofetil, Tacrolimus, Steroids
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2016
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Autologous hematopoietic stem cell transplantation, Cyclophosphamide/ATG, Cyclophosphamide/Rituximab
- Other · Drug
- Lead sponsor
- Scripps Health
- Other
- Eligibility
- 18 Years to 58 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Graft Failure, Sickle Cell Disease, Hemoglobinopathies
- Interventions
- Alemtuzumab, Total Body Irradiation, Cell Infusion, Thymoglobulin, Fludarabine, Busulfan, Cyclophosphamide, Sirolimus, Tacrolimus, Mycophenolate Mofetil, Plerixafor (mozobil)
- Drug · Radiation · Biological
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 55 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2032
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Chronic Lymphocytic Leukemia
- Interventions
- Mylotarg, Fludarabine, Melphalan, Anti-thymocyte globulin, Stem cell transplant
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2006
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Simultaneous Kidney and Pancreas Transplantation
- Interventions
- Belatacept, methylprednisolone, Anti-thymocyte Globulin (Rabbit), Tacrolimus, Mycophenolate mofetil
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • San Francisco, California • Atlanta, Georgia + 2 more
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Busulfan, Cyclophosphamide, Echocardiography Test, Fludarabine, Haploidentical Hematopoietic Cell Transplantation, Lapine T-Lymphocyte Immune Globulin, Lumbar Puncture, Matched Unrelated Donor Hematopoietic Cell Transplantation, Melphalan, Methotrexate, Multigated Acquisition Scan, Mycophenolate Mofetil, Myeloablative Conditioning, Quality-of-Life Assessment, Questionnaire Administration, Rituximab, T-Cell Depletion Therapy, Tacrolimus, Thiotepa, Total-Body Irradiation
- Procedure · Drug · Biological + 2 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 6 Months to 21 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 57
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 49 more
- Conditions
- Acute Myelogenous Leukemia
- Interventions
- aldesleukin, natural killer cells, cyclophosphamide, fludarabine phosphate, allogeneic hematopoietic stem cell transplantation, total body irradiation, Thymoglobulin, Cyclosporin A
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Leukemia, Lymphoma, Bone Marrow Failure, Immunodeficiencies, Histiocytosis, Sickle Cell Disease, Beta Thalassemia, Inborn Errors of Metabolism
- Interventions
- Full Intensity with TBI, Full Intensity, Reduced Intensity, Reduced Intensity (Fanconi)
- Drug
- Lead sponsor
- New York Medical College
- Other
- Eligibility
- Up to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 1
- States / cities
- Valhalla, New York
- Conditions
- Leukemia, Acute Lymphocytic (ALL), Leukemia, Myeloid, Acute(AML), Leukemia, Myeloid, Chronic(CML), Juvenile Myelomonocytic Leukemia (JMML), Hemoglobinuria, Paroxysmal Nocturnal (PNH), Hodgkin Lymphoma, Lymphoma, Non-Hodgkin (NHL), Myelodysplastic Syndrome (MDS)
- Interventions
- CliniMACS, Stem cell transplantation, Fludarabine, Thioplex®, L-phenylalanine mustard, Mycophenolate mofetil, Rituxan™, Alemtuzumab, Cyclophosphamide, Anti-thymocyte globulin (Rabbit), G-CSF, Muromonab
- Device · Procedure · Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2020
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Adult Acute Myeloid Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- Interventions
- filgrastim, Anti-Thymocyte Globulin, busulfan, fludarabine phosphate, methotrexate, tacrolimus, Allogeneic Hematopoietic Stem Cell Transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 60 Years to 74 Years
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2016
- U.S. locations
- 21
- States / cities
- San Francisco, California • Lewes, Delaware • Newark, Delaware + 13 more
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplasia, Chronic Myeloid Leukemia
- Interventions
- Total Body Irradiation, Thiotepa, Fludarabine, Rabbit ATG, Palifermin
- Radiation · Drug · Biological
- Lead sponsor
- Sherif S. Farag
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Kidney Transplant Rejection
- Interventions
- Frexalimab, Tacrolimus, rabbit anti-thymocyte globulin, mycophenolate mofetil, mycophenolate sodium, methylprednisolone, prednisone
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 526 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 11
- States / cities
- Atlanta, Georgia • Hines, Illinois • Kansas City, Kansas + 7 more
- Conditions
- New-onset Type 1 Diabetes Mellitus
- Interventions
- Antithymocyte globulin, Placebo
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Years to 35 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Oakland, California • San Diego, California + 6 more
- Conditions
- Hematologic Malignancy, Acute Leukemia, Remission, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, AML, TP53, Intrachromosomal Amplification of Chromosome 21, Cytogenetic Abnormality, CNS Leukemia, Minimal Residual Disease, Myelodysplasia, Juvenile Myelomonocytic Leukemia, Somatic Mutation, PTPN11 Gene Mutation, N-RAS Gene Amplification, Neurofibromatosis 1, NF1 Mutation, CBL Gene Mutation, Monosomy 7, Chromosome Abnormality, Fetal Hemoglobin, Lymphoblastic Lymphoma, High Grade Non-Hodgkin's Lymphoma, Adult
- Interventions
- Fludarabine, Busulfan, Melphalan, Rituximab, Levetiracetam, Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells, Thymoglobulin, Cyclophosphamide
- Drug · Biological
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 60 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Kidney Diseases
- Interventions
- Not listed
- Lead sponsor
- The University of Texas Medical Branch, Galveston
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2011
- U.S. locations
- 1
- States / cities
- Galveston, Texas
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Lenalidomide, Fludarabine, Rituximab, Thymoglobulin, Stem Cell Transplantation, Bendamustine, Allopurinol
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, Lymphoma
- Interventions
- Fludarabine-Melphalan & Rabbit antithymocyte globulin (r-ATG), Stem Cell Transplant, Stem Cells Collections, Fludarabine, Thiotepa, Antithymocyte globulin (ATG), and Total Body Irradiation (TBI), Fludarabine, Busulfan, and ATG
- Drug · Procedure
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2018
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Liver Failure
- Interventions
- Anti-Thymocyte Globulin, ATG (Rabbit), Total lymphoid irradiation
- Drug · Device
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Heart Transplantation
- Interventions
- Thymoglobulin, Mycophenolate Mofetil, Tacrolimus, Sirolimus, Corticosteroids
- Drug
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 2
- States / cities
- Los Angeles, California
- Conditions
- Sickle Cell Disease
- Interventions
- Haploidentical Bone Marrow Transplantation, Hydroxyurea, Rabbit-ATG, Thiotepa, Fludarabine, Cyclophosphamide, Total Body Irradiation, Mesna
- Procedure · Drug · Radiation
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 5 Years to 45 Years
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Oakland, California • Aurora, Colorado + 24 more
- Conditions
- Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Graft vs. Host Disease (GvHD)
- Interventions
- Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]
- Biological
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Los Angeles, California • Gainesville, Florida + 8 more